文献速递造血干细胞移植与细胞治疗造血干细胞移植与细胞治疗

HLA-B前导序列与HLA错配无关供者移植后的生存

HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation.
PubMed 文献 · Blood · 2020-01-01

该研究分析了1988至2016年间10415例接受单一HLA-A、HLA-B、HLA-C、HLA-DRB1或HLA-DQB1错配无关供者移植患者的HLA-B前导序列基因型,发现患者前导序列基因型对急性GVHD和死亡率的影响因错配HLA位点而异,HLA-DQB1错配MM患者非复发死亡率高于TT患者(HR 1.35,P=0.01),HLA-DRB1错配MM或MT患者III-IV级GVHD风险高于TT患者(OR分别为2.52和1.51)。

要点

  • HLA-DQB1错配MM患者非复发死亡率高于TT患者(HR 1.35,P=0.01)。
  • HLA-DRB1错配MM或MT患者III-IV级GVHD风险高于TT患者(OR 2.52和1.51)。
  • 患者对单一HLA-DQB1错配的耐受优于其他位点错配。

核心结论

  • HLA错配移植后的结局取决于HLA-B前导序列二态性和错配的HLA位点,患者前导序列变异为HLA错配的限制提供了新信息,审慎选择错配供者可能提高HLA错配无关移植的成功率。

研究设计与样本

  • 研究纳入1988至2016年间接受单一HLA-A、HLA-B、HLA-C、HLA-DRB1或HLA-DQB1错配无关供者移植的10415例患者,确定其前导序列基因型。
  • 采用多变量回归方法,按错配HLA位点评估患者前导序列基因型相关风险,并按患者前导序列基因型评估HLA-A、HLA-B、HLA-C、HLA-DRB1或HLA-DQB1错配相关风险。

主要发现

  • 患者前导序列基因型对急性GVHD和死亡率的影响因不同错配HLA位点而异。
  • HLA-DQB1错配MM患者非复发死亡率高于HLA-DQB1错配TT患者(风险比1.35;P=0.01)。
  • HLA-DRB1错配MM或MT患者III-IV级GVHD风险高于HLA-DRB1错配TT患者(比值比分别为2.52和1.51)。
  • 患者对单一HLA-DQB1错配的耐受优于其他位点错配。

关键数值与推荐

  • HLA-DQB1错配MM患者对比TT患者非复发死亡率风险比1.35(P=0.01)。
  • HLA-DRB1错配MM患者对比TT患者III-IV级GVHD比值比2.52。
  • HLA-DRB1错配MT患者对比TT患者III-IV级GVHD比值比1.51。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic cell transplantation (HCT) from HLA-mismatched unrelated donors can cure life-threatening blood disorders, but its success is limited by graft-versus-host disease (GVHD). HLA-B leaders encode methionine (M) or threonine (T) at position 2 and give rise to TT, MT, or MM genotypes. The dimorphic HLA-B leader informs GVHD risk in HLA-B-mismatched HCT. If the leader influences outcome in other HLA-mismatched transplant settings, the success of HCT could be improved for future patients. We determined leader genotypes for 10 415 patients receiving a transplant between 1988 and 2016 from unrelated donors with one HLA-A, HLA-B, HLA-C, HLA-DRB1, or HLA-DQB1 mismatch. Multivariate regression methods were used to evaluate risks associated with patient leader genotype according to the mismatched HLA locus and with HLA-A, HLA-B, HLA-C, HLA-DRB1, or HLA-DQB1 mismatching according to patient leader genotype. The impact of the patient leader genotype on acute GVHD and mortality varied across different mismatched HLA loci. Nonrelapse mortality was higher among HLA-DQB1-mismatched MM patients compared with HLA-DQB1-mismatched TT patients (hazard ratio, 1.35; P = .01). Grades III to IV GVHD risk was higher among HLA-DRB1-mismatched MM or MT patients compared with HLA-DRB1-mismatched TT patients (odds ratio, 2.52 and 1.51, respectively). Patients tolerated a single HLA-DQB1 mismatch better than mismatches at other loci. Outcome after HLA-mismatched transplantation depends on the HLA-B leader dimorphism and the mismatched HLA locus. The patient's leader variant provides new information on the limits of HLA mismatching. The success of HLA-mismatched unrelated transplantation might be enhanced through the judicious selection of mismatched donors for a patient's leader genotype.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Petersdorf EW, Stevenson P, Bengtsson M, et al. HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation. Blood. 2020. PMID: 32483623. doi:10.1182/blood.2020005743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。